Yamanouchi submits hyponatremia agent
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Yamanouchi submits conivaptan NDA for treatment of hyponatremia in January. The first-in-class V1a/V2 vasopressin antagonist qualified for priority review, but the firm said it decided with FDA not to pursue the priority path in favor of an advisory committee review. There are no agents approved for hyponatremia, Yamanouchi says. Approximately 1% to 6% of hospitalized patients are hyponatremic, the majority of which have congestive heart failure...
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.